Radiopharmaceutical Strategies Begin To Take Shape As Field Rolls Into 2025

Radioligand therapies offer a resistance-proof mechanism that complements immuno-therapies and other drug classes. No wonder oncology players continue to pile in.

More from Outlook

More from Market Intelligence